We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $652M
1-Year Est. Return 198.07%
This Fund
S&P 500
This Quarter Est. Return
+104.06%
1 Year Est. Return
+198.07%
3 Year Est. Return
+299.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$504M
AUM Growth
+$170M
Cap. Flow
-$12.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
97.16%
Holding
20
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$157K

Top Sells

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$12.7M
2
VOR icon
Vor Biopharma
VOR
+$40

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.06B
$163M 32.29%
2,449,183
– –
NBTX
2
Nanobiotix
NBTX
$1.92B
$106M 21.08%
5,623,816
– –
MGTX icon
3
MeiraGTx Holdings
MGTX
$1.15B
$54.7M 10.85%
6,641,064
– –
RAPP
4
Rapport Therapeutics
RAPP
$2.04B
$53M 10.52%
1,784,517
-713,534
-29% -$12.7M
CVRX icon
5
CVRx
CVRX
$130M
$33.1M 6.57%
4,103,430
– –
LEGN icon
6
Legend Biotech
LEGN
$4.31B
$26.6M 5.27%
814,586
– –
CTNM
7
Contineum Therapeutics
CTNM
$532M
$23.3M 4.61%
1,979,173
– –
PRCT icon
8
Procept Biorobotics
PRCT
$1.09B
$12.8M 2.54%
357,939
– –
XNCR icon
9
Xencor
XNCR
$1.3B
$8.77M 1.74%
748,062
– –
ARWR icon
10
Arrowhead Research
ARWR
$10.5B
$8.54M 1.69%
247,598
– –
FATE icon
11
Fate Therapeutics
FATE
$324M
$4.26M 0.84%
3,379,064
– –
NMRA icon
12
Neumora Therapeutics
NMRA
$298M
$3.37M 0.67%
1,849,445
– –
VOR icon
13
Vor Biopharma
VOR
$980M
$2.62M 0.52%
53,732
-1
-0% -$40
RLYB icon
14
Rallybio
RLYB
$87.1M
$1.81M 0.36%
454,545
– –
LYEL icon
15
Lyell Immunopharma
LYEL
$326M
$891K 0.18%
54,887
+13,722
+33% +$157K
NNOX icon
16
Nano X Imaging
NNOX
$78M
$588K 0.12%
158,852
– –
LAB icon
17
Standard BioTools
LAB
$350M
$406K 0.08%
311,967
– –
ACET icon
18
Adicet Bio
ACET
$75.9M
$295K 0.06%
22,780
– –
PHGE icon
19
BiomX
PHGE
$2.16M
$50.9K 0.01%
5,098
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$267M
$23.8K ﹤0.01%
2,731
– –

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return
NGM
North Growth Management Vancouver, British Columbia, Canada $653M AUM 88.28% 1-Year Est. Return
RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $651M AUM 15.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Johnson & Johnson's Q3 2025 Portfolio in Review

As of Q3 2025, Johnson & Johnson held 20 positions worth $504M, up 51% from $334M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q3 2025: portfolio turnover was 0%. Johnson & Johnson opened no new positions and made no exits, leaving the 20-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson added most to Lyell Immunopharma in Q3 2025, an estimated $157K increase.
  • Johnson & Johnson's biggest Q3 2025 reduction was Rapport Therapeutics, cutting an estimated $12.7M.
  • Johnson & Johnson's ten largest holdings make up 97% of its $504M portfolio in Q3 2025.
  • Johnson & Johnson opened 0 new positions and closed 0 in Q3 2025.
  • Johnson & Johnson's portfolio value rose 51% quarter-over-quarter to $504M.

Based on Johnson & Johnson's 13F filing for Q3 2025, filed 13 Nov 2025.